Zonisamide for Weight Reduction in Obese Adults.

Trial Profile

Zonisamide for Weight Reduction in Obese Adults.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Zonisamide (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Aug 2013 Results published in JAMA: the Journal of the American Medical Association.
    • 12 Nov 2012 Primary endpoint 'Bodyweight-reduction' has been met for 400 mg/day dosage, according to results in the Archives of Internal Medicine.
    • 12 Nov 2012 Results published in the Archives of Internal Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top